Key facts
- This page summarizes David Bruce Milne's Form 4 filing for ASENSUS SURGICAL, INC..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 22 Aug 2024, 09:11.
David Bruce Milne - 22 Aug 2024 Form 4 Insider Report for ASENSUS SURGICAL, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 22 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Aug 2024, 09:11:04 UTC
- Prior SEC filing
- 08 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joshua Weingard as attorney-in-fact for David Milne
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David Bruce Milne filed Form 4 for ASENSUS SURGICAL, INC. on 22 Aug 2024.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ASXC
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -619,884
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 22 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
David Bruce Milne is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.